<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>23A. Secondary Immunodeficiency & Immunology of HIV infection</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-22b-primary-immunodeficiency.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 76.92%;"></div> <!-- (30/39)*100 -->
                        </div>
                       <span class="progress-text">Lecture 30 of 39</span> 
                    </div>
                    <a href="immunology-23b-secondary-immunodeficiency-handout.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Secondary Immunodeficiency & Immunology of HIV infection</h1>
                <p>Dr. Barasa AK</p>
                <p>130818</p>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: section-secondary-immunodeficiencies-intro -->
                <section id="section-secondary-immunodeficiencies-intro" class="content-section" aria-labelledby="section-heading-secondary-immunodeficiencies-intro">
                    <h2 id="section-heading-secondary-immunodeficiencies-intro" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Secondary Immunodeficiencies</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Acquired defect in one or more components of the immune system that manifests clinically as increased susceptibility to infections</li>
                            <li>Increased susceptibility to common infectious agents & opportunistic infections</li>
                            <li>Symptoms vary depending on degree of immunosuppression & inherent host susceptibility factors</li>
                            <li>Withdrawal of the external condition causing immunodeficiency can result in restoration of immune function</li>
                        </ul>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Predisposing Factors and Specific Causes of Secondary Immunodeficiencies</caption>
                                <thead>
                                    <tr>
                                        <th>Predisposing factors</th>
                                        <th>Specific factors</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Premature and newborn infants</td>
                                        <td>Physiological immunodeficiency due to immaturity of the immune system</td>
                                    </tr>
                                    <tr>
                                        <td>Hereditary and metabolic diseases</td>
                                        <td>Chromosome abnormalities (e.g. Down syndrome), uraemia, DM, malnutrition, vitamin and mineral deficiency, protein-loosing enteropathies, NS, SCD</td>
                                    </tr>
                                    <tr>
                                        <td>Immunosuppressive agents</td>
                                        <td>Radiation, immunosuppressive drugs, corticosteroids</td>
                                    </tr>
                                    <tr>
                                        <td>Infectious</td>
                                        <td>Congenital infections (rubella), viruses (measles, varicella, HIV, CMV, EBV), acute bacterial disease, severe mycobacterial or fungal disease</td>
                                    </tr>
                                    <tr>
                                        <td>Infiltrative and haematological</td>
                                        <td>Histiocytosis, sarcoidosis, lymphoma, leukaemia, myeloma, aplastic anaemia</td>
                                    </tr>
                                    <tr>
                                        <td>Surgery and trauma</td>
                                        <td>Burns, splenectomy</td>
                                    </tr>
                                    <tr>
                                        <td>Miscellaneous</td>
                                        <td>SLE, chronic active hepatitis, alcoholic cirrhosis, ageing</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: section-secondary-immunodeficiencies-intro -->

                <!-- START: section-acquired-hypogammaglobulinemia -->
                <section id="section-acquired-hypogammaglobulinemia" class="content-section" aria-labelledby="section-heading-acquired-hypogammaglobulinemia">
                    <h2 id="section-heading-acquired-hypogammaglobulinemia" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Acquired Hypogammaglobulinaemia</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Young adults</li>
                            <li>Low but detectable levels of total immunoglobulin</li>
                            <li>Normal T cell numbers and function in most cases</li>
                            <li>Rx - immunoglobulin therapy</li>
                            <li>No evidence of genetic transmission, unlike CVID</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-acquired-hypogammaglobulinemia -->

                <!-- START: section-agent-induced-immunodeficiency -->
                <section id="section-agent-induced-immunodeficiency" class="content-section" aria-labelledby="section-heading-agent-induced-immunodeficiency">
                    <h2 id="section-heading-agent-induced-immunodeficiency" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Agent-Induced Immunodeficiency</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Exposure to any of a number of environmental agents that induce an immunosuppressed state</li>
                            <li>Corticosteroids - inhibition of T cell activation, B cell maturation & cytokine synthesis; lymphopaenia</li>
                            <li>Immunosuppressive & cytotoxic drugs (AZA, MTX, 6-MP, cyclophosphamide), Radiotherapy - bone marrow suppression</li>
                            <li>Cyclosporine - inhibits T cell signalling</li>
                            <li>Biologics e.g. rituximab</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-agent-induced-immunodeficiency -->

                <!-- START: section-extremes-of-age -->
                <section id="section-extremes-of-age" class="content-section" aria-labelledby="section-heading-extremes-of-age">
                    <h2 id="section-heading-extremes-of-age" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Extremes of age</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>The very young and the very old</li>
                            <li>Neonates, especially premature babies can be very susceptible to infection,</li>
                            <li>Degree of prematurity linked to the degree of immune dysfunction</li>
                            <li>All the basic immune components are in place in a full-term healthy newborn, but the complete range of innate and adaptive immune functions take some time to mature</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-extremes-of-age -->

                <!-- START: section-malnutrition -->
                <section id="section-malnutrition" class="content-section" aria-labelledby="section-heading-malnutrition">
                    <h2 id="section-heading-malnutrition" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Malnutrition</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Affects both innate and adaptive immunity</li>
                            <li>Low protein-calorie diets (hypoproteinemia) associated with depressed T-cell number & function; deleterious B cell effects may take longer to appear</li>
                            <li>Micronutrient insufficiency (zinc, ascorbic acid) also contributes to immunodeficiency</li>
                            <li>Vitamin D deficiency linked to an inhibition in the ability of macrophages to act against intracellular pathogens e.g. M.tuberculosis</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-malnutrition -->

                <!-- START: section-medical-states -->
                <section id="section-medical-states" class="content-section" aria-labelledby="section-heading-medical-states">
                    <h2 id="section-heading-medical-states" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Medical states</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Splenectomy
                                <ul><li>Antibody deficiency & susceptibility to infections with encapsulated bacteria, malaria, salmonellosis</li></ul>
                            </li>
                            <li>Poor nutrition; surgery/trauma/ICU</li>
                            <li>Protein-loosing states</li>
                            <li>Renal disease</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-medical-states -->

                <!-- START: section-immunology-hiv-infection -->
                <section id="section-immunology-hiv-infection" class="content-section" aria-labelledby="section-heading-immunology-hiv-infection">
                    <h2 id="section-heading-immunology-hiv-infection" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Immunology of HIV Infection</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading" id="hiv-aids-intro">HIV/AIDS</h3>
                        <ul>
                            <li>HIV causes AIDS</li>
                            <li>AIDS first recognized as opportunistic infections in a cluster of individuals on both coasts of the US in June 1981</li>
                            <li>Displayed unusual infections e.g. PJP, previously limited to individuals taking immunosuppressive drugs; KS, a rare skin tumour, etc.</li>
                            <li>Evaluation revealed a deficiency in cell-mediated immune responses and a significant decrease in the CD4<sup>+</sup> T cell subpopulation (T<sub>H</sub> cells)</li>
                            <li>Majority of the patients were homosexual males</li>
                            <li>Others thought to be at risk at that time:
                                <ul>
                                    <li>Promiscuous heterosexual individuals of either sex and their partners</li>
                                    <li>Recipients of blood & blood products prior to 1985</li>
                                    <li>Infants born to HIV-infected mothers</li>
                                </ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading" id="adult-hiv-prevalence">Adult HIV Prevalence, 2015</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-12-1.jpg" alt="World map showing adult HIV prevalence rates by country for 2015. Sub-Saharan Africa shows the highest prevalence." class="content-image">
                        </figure>
                        <h3 class="subsection-heading" id="hiv-aids-epidemic">HIV/AIDS Epidemic</h3>
                        <ul>
                            <li>Approximately 36.7 million people living with HIV at the end of 2016; 2.1 million were children (<15 yr old)</li>
                            <li>1.8 million new infections</li>
                            <li>1 million AIDS-related deaths</li>
                            <li>35 million deaths since the start of the epidemic</li>
                        </ul>
                        <p><strong>Kenya - 4<sup>th</sup> largest epidemic (2016)</strong></p>
                        <ul>
                            <li>1.6 million people living with HIV</li>
                            <li>5.4% adult HIV prevalence</li>
                            <li>62,000 new infections</li>
                            <li>36,000 people died from AIDS-related deaths (64,000 in 2010)</li>
                            <li>64% adults with HIV on ART, 65% children</li>
                        </ul>
                        <h3 class="subsection-heading" id="hiv-1-details">Human Immunodeficiency Virus-1 (HIV-1)</h3>
                        <ul>
                            <li>Retrovirus of the lentivirus genus (displays long incubation periods)</li>
                            <li>Characterized by Luc Montagnier in Paris & Robert Gallo in Bethesda, Maryland, USA (1983)</li>
                            <li>RNA virus; reverse-transcribed to DNA when the virus enters a cells, by the virally coded reverse transcriptase enzyme</li>
                            <li>This copy of DNA is called a provirus; it's integrated into the cell genome and replicated along with the cell DNA</li>
                            <li>When the provirus is expressed to form new virions (viral particles), the cell lyses</li>
                            <li>Alternatively, the provirus may remain latent in the cell until some regulatory signal starts the expression process</li>
                            <li>HIV-2 isolated from AIDS sufferers in Africa about 5 years after the discovery of HIV-1</li>
                            <li>HIV-2 prevalence limited mostly to West Africa; disease progresses much more slowly</li>
                        </ul>
                        <h3 class="subsection-heading" id="structure-hiv">Structure of HIV</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-17-1.jpg" alt="Diagram of HIV structure: lipid envelope with glycoproteins gp120 and gp41, matrix protein p17, capsid protein p24, two RNA strands, and enzymes (reverse transcriptase, integrase, protease)." class="content-image">
                        </figure>
                        <ul>
                            <li>Lipid envelope derives from the host cell; contains some host cell membrane proteins e.g. MHC I & II</li>
                            <li>Env studded by 2 viral glycoproteins, gp120 & gp41 which are important for the infection process</li>
                            <li>Within the env is the viral matrix p17 and the core/nucleocapsid (p24)</li>
                            <li>Genome consists of 2 copies of ssRNA, associated with 2 molecules of RT (p64), a protease (p10) and an integrase (p32) - viral enzymes</li>
                        </ul>
                        <h3 class="subsection-heading" id="hiv-transmission">Transmission</h3>
                        <ul>
                            <li>Intimate contact with body fluids</li>
                            <li>Sexual contact (75%)
                                <ul><li>Unprotected vaginal and anal intercourse</li></ul>
                            </li>
                            <li>Receipt of infected blood or blood products
                                <ul><li>Transfusions, contaminated needles & syringes</li></ul>
                            </li>
                            <li>Perinatal transmission HIV-infected mothers to their infants
                                <ul>
                                    <li>During labour and delivery (in utero)</li>
                                    <li>Breast milk</li>
                                </ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading" id="hiv-spread">Spread</h3>
                        <ul>
                            <li>Direct infection of activated but resting memory CD4<sup>+</sup> T cells present within vaginal mucosa is the likely primary initial source in the FGT (the most studied location)</li>
                            <li>Dendritic cells take up the virus (may not become infected) & transport intact infectious virus to T cells</li>
                            <li>Free virus can also squeeze between epithelial cells or gain access through microabrasions</li>
                            <li>Whether free of cell-associated, the virus migrates through the submucosa to the draining lymph node, where the adaptive immune response can be initiated (& further spread)</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-20-1.jpg" alt="Micrograph showing interaction between a dendritic cell and a T cell, with HIV-1 particles (green dots) clustered at the interface, indicating viral transfer." class="content-image">
                            <figcaption>FIGURE 18-11 Interaction between dendritic cell and T cell, indicating passage of HIV-1 (green dots) between the cells. Note that particles cluster at the interface between the large dendritic cell and the smaller T cell. [Courtesy of Thomas J. Hope, Northwestern University.]</figcaption>
                        </figure>
                        <h3 class="subsection-heading" id="hiv-genome">HIV Genome</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-21-1.jpg" alt="Schematic of the HIV genome, showing the LTRs and genes: gag, pol, env (structural); tat, rev (regulatory); nef, vpu, vpr, vif (accessory)." class="content-image">
                        </figure>
                        <ul>
                            <li>Structural genes: gag, pol, env</li>
                            <li>Regulatory genes/accessory: tat, rev, nef, vpu, vpr, vif</li>
                        </ul>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>HIV Gene Products and Functions (Structural & Enzymatic)</caption>
                                <thead>
                                    <tr>
                                        <th>Gene</th>
                                        <th>Protein product</th>
                                        <th>Function of encoded proteins</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>gag</td>
                                        <td>53-kDa precursor<br>p17<br>p24<br>p9<br>p7</td>
                                        <td>Nucleocapsid proteins<br>Forms outer core-protein layer (matrix)<br>Forms inner core-protein layer (capsid)<br>Is component of nucleoid core<br>Binds directly to genomic RNA</td>
                                    </tr>
                                    <tr>
                                        <td>env</td>
                                        <td>160-kDa precursor<br>gp41<br>gp120</td>
                                        <td>Envelope glycoproteins<br>Is transmembrane protein associated with gp120 and required for fusion<br>Protrudes from envelope and binds CD4</td>
                                    </tr>
                                    <tr>
                                        <td>pol</td>
                                        <td>Precursor<br>$\downarrow$<br>p64<br>p51<br>p10<br>p32</td>
                                        <td>Enzymes<br>Has reverse transcriptase and RNase activity<br>Has reverse transcriptase activity<br>Is protease that cleaves gag precursor<br>Is integrase</td>
                                    </tr>
                                </tbody>
                                <tfoot><tr><td colspan="3">Kuby Immunology, 7<sup>th</sup> edition</td></tr></tfoot>
                            </table>
                        </div>
                        <div class="table-container">
                            <table class="content-table">
                                 <caption>HIV Gene Products and Functions (Regulatory & Auxiliary)</caption>
                                <thead>
                                    <tr>
                                        <th>Gene</th>
                                        <th>Protein product</th>
                                        <th>Function of encoded proteins</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr><td colspan="3"><strong>Regulatory proteins</strong></td></tr>
                                    <tr>
                                        <td>tat</td>
                                        <td>p14</td>
                                        <td>Strongly activates transcription of proviral DNA</td>
                                    </tr>
                                    <tr>
                                        <td>rev</td>
                                        <td>p19</td>
                                        <td>Allows export of unspliced and singly spliced mRNAs from nucleus</td>
                                    </tr>
                                    <tr><td colspan="3"><strong>Auxiliary proteins</strong></td></tr>
                                    <tr>
                                        <td>nef</td>
                                        <td>p27</td>
                                        <td>Down-regulates host-cell class I MHC and CD4</td>
                                    </tr>
                                    <tr>
                                        <td>vpu</td>
                                        <td>p16</td>
                                        <td>Is required for efficient viral assembly and budding. Promotes extracellular release of viral particles, degrades CD4 in ER</td>
                                    </tr>
                                    <tr>
                                        <td>vif</td>
                                        <td>p23</td>
                                        <td>Promotes maturation and infectivity of viral particle</td>
                                    </tr>
                                    <tr>
                                        <td>vpr</td>
                                        <td>p15</td>
                                        <td>Promotes nuclear localization of preintegration complex, inhibits cell division</td>
                                    </tr>
                                </tbody>
                                 <tfoot><tr><td colspan="3">Kuby Immunology, 7<sup>th</sup> edition</td></tr></tfoot>
                            </table>
                        </div>
                        <h3 class="subsection-heading" id="hiv-1-life-cycle">HIV-1 Life Cycle</h3>
                        <ul>
                            <li>Infects cells that carry the CD4 antigen - T<sub>H</sub> cells, monocytes, macrophages</li>
                            <li>High-affinity interaction between gp120 & CD4</li>
                            <li>Expression of a co-receptor required for viral entry - CCR5 or CXCR4 (chemokine receptors)</li>
                            <li>Infection of a T cell assisted by CXCR4, while CCR5 is the preferred coreceptor for viral entry into monocytes and macrophages</li>
                            <li>RNA genome of the virus reverse transcribed & a complementary DNA (cDNA) copy integrates into the host genome</li>
                            <li>The integrated provirus is transcribed</li>
                            <li>The various viral RNA messages are spliced & translated into proteins</li>
                            <li>These initial viral proteins are cleaved by the virally encoded protease into forms that make up the nuclear capsid in a mature infectious viral particle</li>
                            <li>Viral expression leads to newly formed virions that bud from the surface of the infected cell, often causing cell lysis</li>
                            <li>HIV-1 can also become latent or remain unexpressed for long periods of time in an infected cell</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-26-1.jpg" alt="Diagram illustrating the HIV life cycle part (a) Viral Attachment and Entry: 1. gp120 binds CD4. 2. gp41 binds chemokine receptor (CXCR4/CCR5) and fuses. 3. Nucleocapsid enters. 4. Genome and enzymes released. 5. Reverse transcription (ssRNA to RNA-DNA hybrid). 6. dsDNA formation. 7. dsDNA translocates to nucleus and integrates." class="content-image">
                             <figcaption>(a) Infection of target cell. Kuby Immunology, 7<sup>th</sup> edition</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-28-1.jpg" alt="Diagram illustrating the HIV life cycle part (b) Replication and Assembly: 1. Transcription of proviral DNA. 2. Viral RNA exported to cytoplasm. 3a. Synthesis of viral precursor proteins. 3b. Protease cleaves precursors. 4. HIV ssRNA and proteins assemble. 5a. Membrane budding. 5b. Released particles mature." class="content-image">
                            <figcaption>(b) Activation of provirus and production of new virions. Kuby Immunology, 7<sup>th</sup> edition</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-29-1.jpg" alt="Electron micrograph showing HIV particles budding from the surface of an infected T cell." class="content-image">
                            <figcaption>FIGURE 18-14 Once the HIV provirus has been activated, buds representing newly formed viral particles can be observed on the surface of an infected T cell. The extensive cell damage resulting from budding and release of virions leads to the death of infected cells. [Courtesy ofR. C. Gallo, 1988, HIV-The cause of AIDS: An overview on its biology, mechanisms of disease induction, and our attempts to control it. Journal of Acquired Immune Deficiency Syndromes 1:521.]</figcaption>
                        </figure>
                        <h3 class="subsection-heading" id="hiv-pathophysiology-course">Pathophysiology and Clinical Course</h3>
                        <ul>
                            <li>Gradual impairment of immune function & progression to AIDS</li>
                            <li>Isolation of HIV-1 & its growth in culture allowed purification of viral proteins & development of tests for detection infection</li>
                            <li>ELISA - detection of Abs against HIV-1 proteins e.g. gag p24, one of the most immunogenic HIV proteins</li>
                            <li>Antibodies appear in serum of infected individuals within 6-12 weeks after exposure, but can take up to 6 months to appear - seroconversion</li>
                        </ul>
                        <h3 class="subsection-heading" id="dissemination-hiv">Dissemination of HIV</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-31-1.jpg" alt="Diagram illustrating the dissemination of HIV from the initial site of infection (e.g., mucosal surface) to draining lymph nodes, and then systemically via the bloodstream, primarily infecting CD4+ T cells and establishing reservoirs in lymphoid tissues." class="content-image">
                        </figure>
                        <h3 class="subsection-heading" id="typical-course-hiv">Typical Course of HIV Infection</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-32-1.jpg" alt="Graph showing the typical course of HIV infection over years: primary infection (spike in viral load, dip in CD4 cells), clinical latency (stable viral load, gradual CD4 decline), and AIDS (high viral load, very low CD4 cells, opportunistic diseases)." class="content-image">
                            <figcaption>Modified From: Fauci, A.S., et al, Ann. Intern. Med., 124:654, 1996</figcaption>
                        </figure>
                        <h3 class="subsection-heading" id="phases-hiv-infection">Phases of HIV infection</h3>
                        <p>3 phases which occur over 8 to 12 years</p>
                        <ul>
                            <li><strong>Acute/primary infection phase</strong>
                                <ul>
                                    <li>No detectable anti-HIV-1 antibodies</li>
                                    <li>Flu-like symptoms (fever, lymphadenopathy, myalgia, malaise, headache) approximately 2 to 4 weeks after exposure</li>
                                    <li>High rate of viral replication; viral load (number of virions) can be quite high in blood and other body fluids</li>
                                    <li>Decreasing amount of CD4<sup>+</sup> T cells</li>
                                    <li>After a few weeks the immune system catches up controlling viral replication where it remains for several years</li>
                                </ul>
                            </li>
                            <li><strong>Chronic asymptomatic phase/Latency</strong>
                                <ul>
                                    <li>No signs or symptoms of illness</li>
                                    <li>This phase lasts 10 years on average</li>
                                    <li>Gradual decline in CD4<sup>+</sup> T cells</li>
                                    <li>Driven by an immune response involving antibodies & cytotoxic CD8<sup>+</sup> T cells that keep viral replication in check & drive down the viral load</li>
                                    <li>Viral load can be measured by PCR assays for viral RNA</li>
                                </ul>
                            </li>
                            <li><strong>AIDS</strong>
                                <ul>
                                    <li>Acquired Immunodeficiency Syndrome - profound deficiency in T cell immunity</li>
                                    <li>Greatly diminished numbers of CD4+ T cells (<200 cells/µl of blood)</li>
                                    <li>Opportunistic infections - C.albicans, PJP, TB etc</li>
                                    <li>Without ART this phase can lead to death within 2 to 3 years</li>
                                </ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading" id="hiv-cd4-complications">HIV, CD4 Decline, Complications</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-36-1.jpg" alt="Graph illustrating the relationship between declining CD4 T cell count over the course of HIV infection and the increasing risk of opportunistic infections and AIDS-defining illnesses." class="content-image">
                        </figure>
                        <h3 class="subsection-heading" id="mechanism-progression-aids">Mechanism of Progression to AIDS</h3>
                        <ul>
                            <li>Understanding how the immune system holds HIV-1 in check during the asymptomatic phase could aid in the design of effective therapeutic & preventive strategies</li>
                            <li>Long-term nonprogressors (infected individuals who remain asymptomatic for very long periods without treatment) are the subject of intense study</li>
                            <li>Also high-risk populations who remain seronegative despite known & repeated exposure e.g. CSWs</li>
                            <li>Discovery of CCR5 deletion</li>
                            <li>Presence of strong CD8+ T cell responses</li>
                            <li>HLA-associated influences on disease susceptibility</li>
                            <li>Plasma viral loads remain fairly stable throughout the period of chronic HIV infection</li>
                            <li>LN biopsies show high levels of infected cells at all stages of infection, with effacement, long before plasma viral load increases above the steady-state level</li>
                            <li>Lymphoid tissue in the GI tract also depleted - thought to be the main site of HIV-1 replication and CD4<sup>+</sup> T cell depletion</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-39-1.jpg" alt="Comparison of lymph node histology from an uninfected individual (normal architecture) and an HIV-infected individual (showing lymphoid depletion and architectural damage, particularly in the GALT)." class="content-image">
                            <figcaption>1. J. M. Brenchley et al, 2004, CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. Journal of Experimental Medicine 200:749<br>2. Kuby Immunology, 7<sup>th</sup> edition</figcaption>
                        </figure>
                        <h3 class="subsection-heading" id="immunological-abnormalities-hiv">Immunological Abnormalities in HIV/AIDS</h3>
                        <ul>
                            <li>Progressive depletion of CD4<sup>+</sup> T cells</li>
                            <li>Impaired T-cell immunity (even when CD4<sup>+</sup> T cells are present in normal numbers)</li>
                            <li>Impaired mononuclear macrophage function</li>
                            <li>Impaired production of specific antibody despite a polyclonal increase in serum immunoglobulins that lack antibody functions</li>
                        </ul>
                        <h3 class="subsection-heading" id="hiv-immune-activation">HIV infection leads to a state of generalized immune activation</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-41-1.jpg" alt="Diagram illustrating chronic immune activation in HIV infection. Persistent viral replication leads to ongoing stimulation of T cells, B cells, and macrophages, contributing to immune exhaustion and dysfunction despite high levels of activation markers." class="content-image">
                        </figure>
                        <h3 class="subsection-heading" id="cd4-depletion-mechanisms">CD4<sup>+</sup> T Cell Depletion</h3>
                        <ul>
                            <li>Direct viral infection & destruction</li>
                            <li>Half-life of an actively infected CD4<sup>+</sup> T cell is less than 1.5 days</li>
                            <li>Smaller numbers of CD4<sup>+</sup> T cells become infected but do not actively replicate virus; these latently infected cells persist for long periods</li>
                            <li>CD4<sup>+</sup> T cell count (and viral load) are the primary focus of follow-up testing in HIV-infected individuals</li>
                        </ul>
                        <h3 class="subsection-heading" id="other-immunologic-consequences">Other Immunologic Consequences</h3>
                        <ul>
                            <li>Decrease or absence of delayed type hypersensitivity</li>
                            <li>Decreased serum immunoglobulins (especially IgG & IgA)</li>
                            <li>Impaired cellular responses to antigens</li>
                            <li>The HIV-infected individual loses the ability to mount T-cell responses in a predictable sequence
                                <ul>
                                    <li>Responses to specific recall antigens (e.g. influenza virus) are lost first</li>
                                    <li>Then response to alloantigens declines</li>
                                    <li>Finally mitogenic responses to stimuli disappear</li>
                                </ul>
                            </li>
                            <li>Innate responses also impacted, including NK & dendritic cell functions</li>
                        </ul>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>TABLE 18-4 Immunologic abnormalities associated with HIV infection</caption>
                                <thead>
                                    <tr>
                                        <th>Stage of Infection</th>
                                        <th>Typical abnormalities observed</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr><td colspan="2"><strong>LYMPH NODE STRUCTURE</strong></td></tr>
                                    <tr>
                                        <td>Early</td>
                                        <td>Infection and destruction of dendritic cells; some structural disruption, especially to gastrointestinal tractassociated lymphoid tissues</td>
                                    </tr>
                                    <tr>
                                        <td>Late</td>
                                        <td>Extensive damage and tissue necrosis; loss of follicular dendritic cells and germinal centers; inability to trap antigens or support activation of T and B cells</td>
                                    </tr>
                                    <tr><td colspan="2"><strong>T HELPER (T<sub>H</sub>) CELLS</strong></td></tr>
                                    <tr>
                                        <td>Early</td>
                                        <td>Depletion of CD4<sup>+</sup> T cells, especially in the gut (T<sub>H</sub>17 main targets); loss of in vitro proliferative response to specific antigen</td>
                                    </tr>
                                    <tr>
                                        <td>Late</td>
                                        <td>Further decrease in T<sub>H</sub>-cell numbers and corresponding helper activities; no response to T-cell mitogens or alloantigens</td>
                                    </tr>
                                     <tr><td colspan="2"><strong>ANTIBODY PRODUCTION</strong></td></tr>
                                    <tr>
                                        <td>Early</td>
                                        <td>Enhanced nonspecific IgG and IgA production but reduced IgM synthesis</td>
                                    </tr>
                                    <tr>
                                        <td>Late</td>
                                        <td>No proliferation of B cells specific for HIV-1: no detectable anti-HIV antibodies in some patients; increased numbers of B cells with low CD21 expression and enhanced Ig secretion</td>
                                    </tr>
                                    <tr><td colspan="2"><strong>CYTOKINE PRODUCTION</strong></td></tr>
                                    <tr>
                                        <td>Early</td>
                                        <td>Increased levels of some cytokines</td>
                                    </tr>
                                    <tr>
                                        <td>Late</td>
                                        <td>Shift in cytokine production from T<sub>H</sub>1 subset to T<sub>H</sub>2 subset</td>
                                    </tr>
                                    <tr><td colspan="2"><strong>DELAYED-TYPE HYPERSENSITIVITY</strong></td></tr>
                                    <tr>
                                        <td>Early</td>
                                        <td>Highly significant reduction in proliferative capacity of T<sub>H</sub>1 cells and reduction in skin-test reactivity</td>
                                    </tr>
                                    <tr>
                                        <td>Late</td>
                                        <td>Elimination of DTH response; complete absence of skin-test reactivity</td>
                                    </tr>
                                    <tr><td colspan="2"><strong>T CYTOTOXIC (T<sub>C</sub>) CELLS</strong></td></tr>
                                    <tr>
                                        <td>Early</td>
                                        <td>Normal reactivity</td>
                                    </tr>
                                    <tr>
                                        <td>Late</td>
                                        <td>Reduction but not elimination of CTL activity due to impaired ability to generate CTLs from T<sub>C</sub> cells</td>
                                    </tr>
                                </tbody>
                                 <tfoot><tr><td colspan="2">Kuby Immunology, 7<sup>th</sup> edition</td></tr></tfoot>
                            </table>
                        </div>
                        <h3 class="subsection-heading" id="hiv-therapeutic-targets">Therapeutic targets to inhibit HIV replication</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_f1dc6931b2e709d97ac8g-46-1.jpg" alt="Diagram of the HIV life cycle highlighting various points that can be targeted by antiretroviral drugs: entry/fusion inhibitors, reverse transcriptase inhibitors (NRTIs, NNRTIs), integrase inhibitors, and protease inhibitors." class="content-image">
                        </figure>
                        <h3 class="subsection-heading" id="antiretroviral-therapy">Antiretroviral Therapy</h3>
                        <ul>
                            <li>HAART/cART - use of 3 or more anti-HIV drugs from different classes, to overcome the ability of the virus to rapidly produce drug resistant mutants</li>
                            <li>In many cases, cART has lowered plasma viral loads to undetectable levels</li>
                            <li>Virus may persist in sites that are not readily penetrated by ART, e.g. brain, thereby making it difficult to eradicate all virus from an infected individual and cure AIDS</li>
                        </ul>
                        <h3 class="subsection-heading" id="hiv-vaccine-challenges">A vaccine may be the only way to stop the HIV/AIDS epidemic</h3>
                        <ul>
                            <li>Prevent infection and/or progression to disease</li>
                            <li>Challenges to vaccine development
                                <ul>
                                    <li>Rapid mutation of HIV-1 (many variants)</li>
                                    <li>Neutralizing antibodies do not necessarily inhibit viral spread</li>
                                    <li>Limited animal models</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-immunology-hiv-infection -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-22b-primary-immunodeficiency.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 76.92%;"></div> 
                        </div>
                       <span class="progress-text">Lecture 30 of 39</span> 
                    </div>
                    <a href="immunology-23b-secondary-immunodeficiency-handout.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> 
</body>
</html>